Form 4: Mineralys Therapeutics Director Brian Taylor Slingsby Reports Transaction
SEC Form 4 Filing
Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, reported the disposition of 550,000 shares of common stock at a price of $13.05 on July 24, 2024.
Summary
- On July 24, 2024, Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, disposed of 550,000 shares of common stock.
- The transaction was executed at a price of $13.05 per share.
- Following the transaction, Slingsby indirectly owns 8,644,579 shares through Catalys Pacific Fund, LP.
Sentiment
Score: 5
Explanation: This is a neutral report of a stock transaction. The sentiment is neither positive nor negative as it simply reflects a change in ownership.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to the market.
Stakeholder Impact
- The transaction could potentially influence investor sentiment, depending on how the market interprets the insider's sale of shares.
Key Dates
| Date | Description |
|---|---|
| 07/24/2024 | Date of the stock transaction (disposition of shares). |
| 07/26/2024 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.